Clinical Trial Update: Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for tegavivint in recurrent or refractory solid tumors, including lymphomas and desmoid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Desmoid-type Fibromatosis
• Endometrial Cancer
• Melanoma
• Neuroblastoma
• Non-hodgkin Lymphoma
• Ovarian Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Tegavivint

Snippet

Sponsor: Children's Oncology Group | Conditions: Colorectal Carcinoma, Endometrial Carcinoma | Phase 1, Phase 2 | Status: RECRUITING